Alaunos Therapeutics (NASDAQ:TCRT) released proof-of-concept data from two separate diet-induced obesity (DIO) mouse studies on Monday, marking a strategic pivot toward non-hormonal metabolic treatments.
The company’s lead candidate, ALN1003, demonstrated a dose-dependent reduction in body weight that reached a peak loss of 12.9% relative to untreated controls by day 34 of the study.
The results highlight a potential alternative to current GLP-1 and GIP-based injectable therapies.
Beyond weight reduction, ALN1003 showed a profound impact on liver health, with total liver weights falling by as much as 55% in the high-dose group.
Metabolic markers also trended favorably, with blood glucose levels dropping to 197 mg/dL from a baseline of 320 mg/dL, alongside a measurable reduction in total cholesterol levels.
Despite the promising laboratory outcomes, Alaunos faces a constrained timeline to advance the program into human testing.
The company reported a cash balance of approximately $1.9 million as of September 30, 2025, which management estimates provides an operational runway into the second quarter of 2026.
This limited liquidity necessitates near-term capital raising or strategic partnerships to fund the required Chemistry, Manufacturing, and Controls (CMC) work and IND-enabling studies.
Looking ahead, Alaunos plans to refine the formulation of ALN1003 and explore next-generation chemistry to optimize the molecule's profile.
The company is currently prioritizing its preclinical pipeline and CMC activities to prepare for a potential Investigational New Drug application, provided it can secure the necessary financing to bridge its current cash gap.